Rezultati pretraživanja
  1. prije 9 sati

    If you did not believe in strains before, think again! New paper shows differences in CSF between and . and insight into -like biology?

    Lewy body
  2. Our top story this week: (), & team report that a simple one-off may dictate the success of intensive glucose control in people with . Read more on the analysis of the ACCORD trial here:

  3. And THAT would explain the 13G out (institutional buying) news

    Prikaži ovu nit
  4. prije 16 sati

    BioAgilytix team members will be in attendance at ’s 2020 Oxford Global Biomarkers Series UK from 18-20 February. Visit Booth #30 & join Dr. Afshin Safavi for his presentation covering Exploratory Testing on 19 Feb:

  5. prije 17 sati

    Researchers from are developing tests to detect early, monitor therapeutic efficacy and predict outcomes – making and more precise.

  6. 4. velj

    Are the next big ? We think so, and our Nu.Q™ H3.1 assay kit is the best way to study nucleosomes containing H3.1 in samples. Learn more:

  7. 4. velj

    A large multicentric study has identified a new biomarker that could be used in the differential diagnosis of vascular dementia from Alzheimer's disease. Learn more here

  8. 4. velj

    News: A simple one-off could help to gauge the risk–benefit ratio of intensive glucose control in people with , (), and study co-authors report in

  9. 3. velj
  10. 3. velj
  11. 2. velj
  12. 1. velj
  13. 1. velj

    Join Paragon Genomics at 5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference in San Diego next week. See how ultra-high multiplex PCR technology might be applied to your discovery and development.

  14. 31. sij
  15. 31. sij
  16. 31. sij

    A newly identified biomarker could facilitate the differential diagnosis of vascular dementia, according to the results of a large multicenter study. Learn more here

  17. 30. sij

    See how Ella was used to evaluate pNF-H levels in the plasma and CSF of a presymptomatic spinal muscular atrophy (SMA) population to assess the value of pNF-H as a potential of treatment response to SMN-enhancing therapies.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.